ASND logo

Ascendis Pharma A/S (ASND) Company Overview

Profile

Full Name:

Ascendis Pharma A/S

Sector:

Healthcare

Industry:

Biotechnology

Country:

Denmark

IPO:

January 28, 2015

Indexes:

Not included

Website:

http://ascendispharma.com

Description:

Ascendis Pharma A/S is a biotechnology company focused on developing innovative therapies for rare diseases and endocrine disorders. They use their unique TransCon technology to create long-acting treatments, aiming to improve patient outcomes and quality of life through advanced drug delivery systems.

Key Details

Price

$144.56

Market Cap

$8.65 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$393.59 M(+36.31% YoY)

Annual EPS

-$7.07(+23.64% YoY)

PE Ratio

-

Annual ROE

372.04%

Annual Debt To Equity

-8.10

Beta

0.85

Events Calendar

Earnings

Next earnings date:

May 2, 2025

Recent quarterly earnings:

Feb 12, 2025

Recent annual earnings:

Feb 12, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 25, 25 Cantor Fitzgerald
Overweight
Feb 18, 25 Evercore ISI Group
Outperform
Feb 13, 25 JP Morgan
Overweight
Feb 13, 25 Goldman Sachs
Buy
Feb 11, 25 Cantor Fitzgerald
Overweight
Jan 29, 25 JP Morgan
Overweight
Jan 7, 25 UBS
Buy
Nov 15, 24 Wedbush
Outperform
Nov 15, 24 TD Cowen
Buy
Nov 15, 24 Stifel
Buy

Screeners with ASND included

Growing Shares Outstanding
Mid cap stocks
Best performing stocks last 3 months
Best performing stocks last 5 years
Stocks above SMA 50
Healthcare sector
All stocks
NASDAQ Listed Companies
Biotechnology industry
Stocks above SMA 200

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$144.56
ASND price is $144.56

Price All-time High

$182.76
ASND price is currently -20.90% below its historical high of $182.76

Price Analysts Target

-
ASND price consensus analysts' forecast is unknown

Price Most Recent Change

-4.59%
ASND price was down -4.59% on Mar 8, 2025

Price YTD Change

+5%
ASND price is up +5% since January 1st

Price 3-Year Change

+36.95%
ASND price is up +36.95% over the past 3 years

Market cap

Market Cap

$8.65 B
ASND market capitalization is $8.65 billion

Market Cap 3-Year Change

+44.33%
ASND market capitalization is up +44.33% over the past 3 years

Market Cap All-time High

$9.76 B
ASND market capitalization is currently -11.38% below its historical high of $9.76 billion

Market Cap Sector Rank

91.36%
ASND market capitalization is higher than 91.36% of companies in Healthcare sector

Technical

Beta

0.85
ASND beta is 0.85

200-day SMA

$133.86
ASND price is currently +7.99% above its 200-day simple moving average

14-day RSI

51.50
ASND 14-day relative strength index is 51.50

30-day Relative Volume

0.70
ASND 30-day relative volume is 0.70

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$393.59 M
ASND annual revenue is $393.59 million

Annual Revenue Analysts Estimate

$566.43 M
ASND annual revenue is currently -30.51% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+36.31%
ASND annual revenue is up +36.31% year-on-year

Annual Revenue Sector Rank

71.91%
ASND annual revenue is higher than 71.91% of companies in Healthcare sector

Profit

Annual Gross Profit

$345.68 M
ASND annual gross profit is $345.68 million

Annual Gross Margin

87.83%
ASND annual gross profit margin is 87.83%

Annual Operating Profit

-$301.72 M
ASND annual operating income is -$301.72 million

Annual Operating Margin

-76.66%
ASND annual operating profit margin is -76.66%

Annual Net Income

-$409.22 M
ASND annual net profit is -$409.22 million

Annual Net Margin

-103.97%
ASND annual net profit margin is -103.97%

EPS

Annual EPS

-$7.07
ASND annual earnings per share is -$7.07

Annual EPS Analysts Estimate

-$3.48
ASND annual earnings per share is currently +103.26% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+23.64%
ASND annual earnings per share is up +23.64% year-on-year

Annual EPS Sector Rank

17.67%
ASND annual earnings per share is higher than 17.67% of companies in Healthcare sector

ROA & ROE

Annual ROA

-38.25%
ASND annual return on assets is -38.25%

Annual ROE

372.04%
ASND annual return on equity is 372.04%

EBIT & EBITDA

Annual EBIT

-$333.08 M
ASND annual earnings before interest & taxes is -$333.08 million

Annual EBITDA

-$313.91 M
ASND annual EBITDA is -$313.91 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
ASND price to earnings ratio value is unknown

PE Ratio Sector Rank

-
ASND price to earnings ratio is unknown

PB Ratio

PB Ratio

-78.65
ASND price to book ratio is -78.65

PB Ratio Sector Rank

0.49%
ASND price to book ratio is higher than 0.49% of companies in Healthcare sector

PS Ratio

PS Ratio

22.07
ASND price to sales ratio is 22.07

PS Ratio Sector Rank

86.7%
ASND price to sales ratio is higher than 86.7% of companies in Healthcare sector

Enterprise value

Enterprise Value

$8.96 B
ASND enterprise value is $8.96 billion

Enterprise Value Sector Rank

90.71%
ASND enterprise value is higher than 90.71% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-33.69
ASND EV/EBITDA is -33.69

EV/EBITDA Sector Rank

4.12%
ASND EV/EBITDA is higher than 4.12% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

1.17
ASND annual current ratio is 1.17

Annual Quick Ratio

0.84
ASND annual quick ratio is 0.84

Leverage

Annual Debt To Equity

-8.10
ASND annual debt to equity ratio is -8.10

Annual Interest Coverage Ratio

-4.70
ASND annual interest coverage ratio is -4.70

Risk & Stability

Piotroski F-Score

-
ASND piotroski f-score value is unknown

Altman Z-Score

-
ASND altman z-score value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$1.23 B
ASND annual total assets is $1.23 billion

Annual Non Current Assets

$123.45 M
ASND annual long term assets is $123.45 million

Annual Current Assets

$1.10 B
ASND annual total current assets is $1.10 billion

Annual Cash & Cash Equivalents

$582.24 M
ASND annual cash & cash equivalents is $582.24 million

Equity

Annual Book Value

-$109.99 M
ASND annual book value is -$109.99 million

Annual Working Capital

$159.21 M
ASND annual working capital is $159.21 million

Liabilities

Annual Total Liabilities

$1.34 B
ASND annual total liabilities is $1.34 billion

Annual Total Long Term Liabilities

$392.65 M
ASND annual total long term liabilities is $392.65 million

Annual Current Liabilities

$944.70 M
ASND annual total current liabilities is $944.70 million

Annual Accounts Payable

$100.30 M
ASND annual accounts payable is $100.30 million

Debt

Annual Total Debt

$891.37 M
ASND annual total debt is $891.37 million

Annual Total Debt 1-Year Change

+25.16%
ASND annual total debt is up +25.16% year-on-year

Annual Long Term Debt

$379.89 M
ASND annual long term debt is $379.89 million

Annual Short Term Debt

$511.48 M
ASND annual short term debt is $511.48 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$695.31 M
ASND annual total expenses is $695.31 million

Annual Operating Expenses

$647.40 M
ASND annual total operating expenses is $647.40 million

Annual Cost Of Goods Sold

$47.90 M
ASND annual cost of goods sold is $47.90 million

Annual SGA

$307.98 M
ASND annual SGA is $307.98 million

Annual D&A

$19.17 M
ASND annual depreciation & amortization is $19.17 million

Annual Interest Expense

$70.90 M
ASND annual interest expense is $70.90 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$331.41 M
ASND annual cash flow from operations is -$331.41 million

Annual CFO 1-Year Change

+34.5%
ASND annual cash flow from operations is up +34.5% year-on-year

Annual CFI

$7.44 M
ASND annual cash flow from investing activities is $7.44 million

Annual CFI 1-Year Change

-97.6%
ASND annual cash flow from investing activities is down -97.6% year-on-year

Annual CFF

$480.49 M
ASND annual cash flow from financing activities is $480.49 million

Annual CFF 1-Year Change

+230.49%
ASND annual cash flow from financing activities is up +230.49% year-on-year

Free CashFlow

Annual FCF

-$332.96 M
ASND annual free cash flow is -$332.96 million

Annual FCF 1-Year Change

+34.54%
ASND annual free cash flow is up +34.54% year-on-year

CAPEX

Annual CAPEX

$1.54 M
ASND annual capital expenditures is $1.54 million

Annual CAPEX 1-Year Change

-41.58%
ASND annual capital expenditures is down -41.58% year-on-year

Institutional Ownership

Similar stocks

RGEN logo
Repligen (RGEN)
QGEN logo
Qiagen NV (QGEN)
HQY logo
HealthEquity (HQY)
CHE logo
Chemed (CHE)
JAZZ logo
Jazz Pharmaceuticals (JAZZ)
EXAS logo
Exact Sciences (EXAS)
TEM logo
Tempus AI (TEM)
CRL logo
Charles River Laboratories International (CRL)
PCVX logo
Vaxcyte (PCVX)

FAQ

  • What is the ticker symbol for Ascendis Pharma A/S?
  • Does Ascendis Pharma A/S pay dividends?
  • What sector is Ascendis Pharma A/S in?
  • What industry is Ascendis Pharma A/S in?
  • What country is Ascendis Pharma A/S based in?
  • When did Ascendis Pharma A/S go public?
  • Is Ascendis Pharma A/S in the S&P 500?
  • Is Ascendis Pharma A/S in the NASDAQ 100?
  • Is Ascendis Pharma A/S in the Dow Jones?
  • When was Ascendis Pharma A/S's last earnings report?
  • When does Ascendis Pharma A/S report earnings?

What is the ticker symbol for Ascendis Pharma A/S?

The ticker symbol for Ascendis Pharma A/S is NASDAQ:ASND

Does Ascendis Pharma A/S pay dividends?

No, Ascendis Pharma A/S does not pay dividends

What sector is Ascendis Pharma A/S in?

Ascendis Pharma A/S is in the Healthcare sector

What industry is Ascendis Pharma A/S in?

Ascendis Pharma A/S is in the Biotechnology industry

What country is Ascendis Pharma A/S based in?

Ascendis Pharma A/S is headquartered in Denmark

When did Ascendis Pharma A/S go public?

Ascendis Pharma A/S's initial public offering (IPO) was on January 28, 2015

Is Ascendis Pharma A/S in the S&P 500?

No, Ascendis Pharma A/S is not included in the S&P 500 index

Is Ascendis Pharma A/S in the NASDAQ 100?

No, Ascendis Pharma A/S is not included in the NASDAQ 100 index

Is Ascendis Pharma A/S in the Dow Jones?

No, Ascendis Pharma A/S is not included in the Dow Jones index

When was Ascendis Pharma A/S's last earnings report?

Ascendis Pharma A/S's most recent earnings report was on Feb 12, 2025

When does Ascendis Pharma A/S report earnings?

The next expected earnings date for Ascendis Pharma A/S is May 2, 2025